作者
Christopher S Foster, Alison Falconer, Andrew R Dodson, Andrew R Norman, Nening Dennis, Anne Fletcher, Christine Southgate, Anna Dowe, David Dearnaley, Sameer Jhavar, Rosalind Eeles, Andrew Feber, Colin S Cooper
发表日期
2004/8
期刊
Oncogene
卷号
23
期号
35
页码范围
5871-5879
出版商
Nature Publishing Group
简介
E2F transcription factors, including E2F3, directly modulate expression of EZH2. Recently, overexpression of the EZH2 gene has been implicated in the development of human prostate cancer. In tissue microrarray studies we now show that expression of high levels of nuclear E2F3 occurs in a high proportion (98/147, 67%) of human prostate cancers, but is a rare event in non-neoplastic prostatic epithelium suggesting a role for E2F3 overexpression in prostate carcinogenesis. Patients with prostate cancer exhibiting immunohistochemically detectable nuclear E2F3 expression have poorer overall survival (P= 0.0022) and cause-specific survival (P= 0.0047) than patients without detectable E2F3 expression. When patients are stratified according to the maximum percentage of E2F3-positive nuclei identified within their prostate cancers (up to 20, 21–40%, etc.), there is an increasingly significant association between …
引用总数
2005200620072008200920102011201220132014201520162017201820192020202120222023131917141117713121617811848343